SIU 2017: The Prognostic Implication of Body Mass Index on Postoperative Survival Outcomes in Non-Metastatic Renal Cell Carcinoma

Lisbon, Portugal ( Obesity is well-known risk factor for the development of renal cell carcinoma (RCC). However, the impact of obesity on patients' survival outcomes after nephrectomy has not been clearly established thus far. The authors aimed to evaluate the association between body mass index (BMI) and Survival outcomes in patients with non-metastatic RCC, including overall survival (OS), cancer specific survival (CSS), and recurrence free survival (RFS).

SIU 2017: The Predictive Value of Preoperative AST/ALT Ratio in Renal Cell Carcinoma Patients – A Multicenter Study

Lisbon, Portugal ( There is some controversial evidence suggesting that the AST/ALT ratio, performed prior to surgery, in patients with renal cell carcinoma (RCC), has some correlation to prognosis. In this study the authors analyzed the value of this preoperative ratio as a possible predictive factor in RCC.

SIU 2017: Cytoreductive Nephrectomy in the Era of Tyrosine Kinase Inhibitors: Is It the Standard?

Lisbon, Portugal ( In this State-of-the-Art Lecture, Dr. Uzzo discusses the role of cytoreductive nephrectomy in the era of targeted therapy. Of note, he makes a distinction between cytoreductive nephrectomy (up-front cytoreduction followed by systemic therapy) vs. consolidative nephrectomy (initial systemic therapy, nephrectomy if requested due to good response). 

SIU 2017: Is It Always Necessary to Perform Restaging TUR for cT1 Urothelial Carcinoma of the Bladder?

Lisbon, Portugal ( In this State-of-the-Art lecture, Dr. Palou addresses the question of repeat TURBT for staging in patients with initial diagnosis of pT1 Urothelial Bladder Cancer. 

The rate of incomplete resection, and therefore understaging, has always been cited as the primary reason to pursue a re-resection. Meta-analyses have identified residual disease on re-resection at rates up to 61%, though even at its best, at least 25%. The understaging resulting in missed pT2 disease is the most worrisome component, and meta-analyses have demonstrated understaging rates of approximately 15%. 

SIU 2017: The Role of Lymphadenectomy in the Oligometastatic and Salvage Prostate Cancer Setting

Lisbon, Portgual ( In this State-of-the-Art lecture, Dr. Heidenreich provided an insightful presentation into the role of lymphadenectomy in the oligometastatic and salvage prostate cancer setting, as it evolves over time. 

SIU 2017: Long-Term Outcomes Following Laparoscopic Radiofrequency Ablation for T1a Renal Cell Carcinoma

Lisbon, Portugal ( Few studies have reported long-term outcomes of renal cell carcinoma (RCC) treated by radiofrequency ablation (RFA). The authors have reviewed their experience with cTla renal masses treated with laparoscopic RFA.

SIU 2017: The Role of Renal Biopsy in Management of Small Renal Masses

Lisbon, Portugal ( The management of small renal masses (SRMs) has been assisted by the increased use of renal mass biopsy (RMB) which can avoid unnecessary surgical intervention.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.